Nutritional or pharmacological activation of HCA2 ameliorates neuroinflammation

N/ACitations
Citations of this article
172Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Neuroinflammation is a pathology common to many neurological diseases, including multiple sclerosis (MS) and stroke. However, therapeutic attempts to modulate neuroinflammation have proved difficult. Neuroinflammatory cells express HCA2, a receptor for the endogenous neuroprotective ketone body β-hydroxybutyrate (BHB) as well as for the drugs dimethyl fumarate (DMF) and nicotinic acid, which have established efficacy in the treatment of MS and experimental stroke, respectively. This review summarizes the evidence that HCA2 is involved in the therapeutic effects of DMF, nicotinic acid, and ketone bodies in reducing neuroinflammation. Furthermore, we discuss the mechanisms underlying the beneficial effects of HCA2 activation in neuroinflammatory diseases and the therapeutic potential of recently developed synthetic ligands of HCA2.

Cite

CITATION STYLE

APA

Offermanns, S., & Schwaninger, M. (2015, April 1). Nutritional or pharmacological activation of HCA2 ameliorates neuroinflammation. Trends in Molecular Medicine. Elsevier Ltd. https://doi.org/10.1016/j.molmed.2015.02.002

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free